ADC Therapeutics SA (NYSE:ADCT) Shares Could Be 50% Below Their Intrinsic Value Estimate

The analyst's price target for ADC Therapeutics is 59% higher than their estimated fair value. A Discounted Cash Flow model is used to determine the intrinsic value of the stock, showing it to be undervalued at a 50% discount to the current share price.